Signaling networks in cancer - an interview with Christian Gespach

OLIVIER DE WEVER*
Laboratory of Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium

ABSTRACT The dynamic, innovative temperament of Christian Gespach is ideally suited to unraveling some aspects of the complex molecular networks connected with signal transduction, cancer progression and treatment. He is one of the pioneers who opened, in the early 1980s, new insights into the signaling mechanisms of G-protein coupled receptor (GPCR) activation, desensitization, internalisation and crosstalks. Twenty five years later and in collaboration with Gespach, IPSEN pharmaceuticals designed pan-inhibitors of GPCR signaling, targeting G\(_\alpha\) subunits in breast cancer progression and other epithelial cancers. Creativity is of vital importance to understand signal transduction pathways engaged in cancer cell motility, invasion and drug resistance. Christian Gespach has published more than 200 papers in cancer research, a true signal transduction tale.

KEY WORDS: interview, molecular network, GPCR, motility

Christian Gespach started his lifetime dedication to Science and Medical Research as a Pierre and Marie Curie student in 1967 (University Paris VI, France). During University training he worked in a full time position at the French National Education Colleges in Paris and Créteil Academy (1968-1976). He subsequently performed his graduate studies in Hospital Saint-Antoine (INSERM U55 laboratory), where he was involved in projects aiming at elucidating the role of glucose, incretins and neuropeptides in the biosynthesis and secretion of pancreatic hormones (1975-1977). As a PhD graduate, he joined the laboratory of Dr. Jean-Pierre Abita at INSERM U204 (1979-1987), Hospital Saint-Louis (signal transduction in normal and leukemic hematopoietic cells) to work on histamine \(H2\) receptors, neutrophil chemotaxis and differentiation of leukemic cells by retinoic acid, vitamin D3 and bile acids (Zimmer et al., 2000). In 1979, he obtained a staff position at INSERM in Paris, where he continued to work on signal transduction in normal and cancerous digestive epithelial cells and leukemic cells (State Doctorate in Sciences, 1986).

My first contact with Christian Gespach was via a telephone conference in 2001. During this period, we had several interactions concerning the role of myofibroblasts in colon cancer invasion. Proof of the fruitful discussions was the publication of the work in FASEB Journal and Journal of Cell Science (De Wever et al., 2004a, De Wever et al., 2004b). After my PhD in 2004, I was fortunate to organize multiple long term and short term yearly visits to the Gespach lab. Paris is only 300 km away from Ghent and luckily we have a direct fast train connection. A two hour trip brings you from Ghent in Paris Nord train station. My first stay covered about 8 weeks in late May till early July of 2004. I stayed in a picturesque house in Périgny-sur-Yerres, a suburb 25 km to the south of Paris. One of the crazy experiments during those days was a bicycle trip during rush hour from Périgny to the host lab, located in the center of Paris. The Gespach lab had a driving scientific atmosphere with multiple successful young lab members such as Samir Attoub, Quang-Dé Nguyen, Sylvie Rodrigues, Nathalie Le Floch, Christelle Rodrigue and Christine Rivat. I was honoured to perform experiments with so many creative minds educated by Christian Gespach. This visit formed a solid basis for multiple future publications and collaborative efforts.

In December, 2010 Christian Gespach was invited to the Ghent laboratory of Experimental Cancer Research to discuss recent collaborative data. The day started with discussing a future strategy about the NM23 metastasis suppressor. This project was engaged under mutual interactions with Dr. Mathieu Boissan and Dr. Marie-Lise Lacomme in Hospital Saint-Antoine, INSERM U938 showing that the metastasis suppressor NM23H1 is involved in the maintenance of E-cadherin-based adherens junctions and control of epithelial cancer cell scattering and adhesion in primary tumors (Boissan et al., 2010). We continued the discussion about the cross-signaling between bone marrow-derived mesenchymal stem cells and colon cancer cells. Only at the end of the day I managed to squeeze in a few of my questions!

Abbreviations used in this paper: GPCR, G-protein coupled receptor.

*Address correspondence to: Olivier De Wever. Laboratory of Experimental Cancer Research, Ghent University Hospital 1P7, De Pintelaan 185, 9000 Gent, Belgium Tel: +32-9-332-3073. e-mail: Olivier.dewever@ugent.be

Final, author-corrected PDF published online: 29 November 2011
Did your family have a strong scientific tradition?

My family was not involved in practical or experimental medicine but was mainly working in accounting expertise and commercial banking.

When did you enter into the field of cell signaling?

I was scientifically born as a researcher in the laboratory of Dr. Gabriel Rosselin (INSERM U55) working on Diabetes and Digestive Diseases (membrane receptors, signal transduction and cyclic nucleotides cAMP /cGMP).

Christian Gespach is one of the pioneers who opened, in the early 1980s, new insights in the signaling mechanisms of G-protein coupled receptors (GPCRs) activation, desensitization, internalisation and crosstalks (VIP and histamine H2 receptor regulation by somatostatin).

As shown in Fig. 1, the G-proteins Gα and Gβγ signaling systems downstream GPCR cycle between ligand activated Gα-GTP + Gβγ subunits and return to the Gα-GDP /Gβγ heterotrimeric, inactivated state. The GTP-bound activated state of Gα proteins can be mimicked by aluminium fluoride (AlF4-) and the nonhydrolyzable GTP analogues GTP-γS and GDP-NH2 (Fig. 2).

Relations of GPCR signaling with oncogenic pathways and functional defects associated with the progression of epithelial cancers were analyzed by Gespach et al., in normal, immortalized and transformed epithelial cells of the colon, stomach and breast (Gespach et al., 1980, Gespach et al., 1981a, Gespach et al., 1981b). Twenty five years later and in collaboration with Gespach, IPSEN pharmaceuticals designed pan-inhibitors of GPCR signaling targeting Gα subunits in the MCF-7 breast cancer cell line and the invasive growth of epithelial cancer cells and tumors (Ayoub et al., 2009, Prevost et al., 2006) (Fig. 3). Many GPCR signals are connected with critical dysfunctions inherent to leukocyte and epithelial cell chemotaxis and oncogenesis. First attempts to control cancer progression by targeting a given GPCR were unsuccessful because of the multifactorial nature and partial redundancy of the genetic and molecular defects driving neoplasia. Recently, the therapeutic anti-cancer potential of these small molecule signaling inhibitors downstream GPCR has been documented by other groups targeting Gβγ subunits. GPCR and their signal transduction systems are involved in normal development, various physiopathological states and are now considered as canonical oncogenic pathways in breast cancers and clinical tumors (Fig. 4). At the end of the nineties, Gespach laboratories have made significant advances in molecular and clinical oncology of epithelial tumors in breast, gastrointestinal tract and urogenital systems. For example, Dr. Gespach contributed to the elucidation of several mechanisms involved in gene expression (TCF/LEF1-β-catenin and c-Jun/AP-1 synergy, STAT-3 signaling), cancer cell differentiation, invasive growth, tumor angiogenesis, metastasis and chemoresistance. This was accomplished at the

![Fig. 1. G-protein coupled receptor (GPCR) signaling and the Gα-GDP /Gα-GTP cycle of the heterotrimeric G-proteins (hGP).](image)

The G-protein concept of GTPases transducers cycling from GTP /GDP intermediates originates from the original discovery of Martin Rodbell and Alfred Gilman (Nobel prize laureates, 1994). Both heterotrimeric G-proteins (hGP) downstream GPCR and Ras superfamily small G-proteins downstream growth factor receptors are playing crucial roles in normal development and malignant transformation. Latent Gαβγ heterotrimeric G-proteins are membrane-associated under predominant inactive Gα-GDP /Gβγ heterotrimers. Upon interaction and activation by a given selective ligand agonist, G-protein coupled receptors (GPCR) promote GPCR- hGP interaction and the GDP /GTP exchange at Gα subunits through G-protein exchange factors GEFs, leading to decreased affinity of Gα-GTP for Gβγ and promoting their dissociation. Then, activated Gα-subunits, Gβγ dimers, Gα-and Gβ monomers activate several downstream signaling elements and effectors such as adenylyl cyclases (Gαs, Gαolf), GTPases (Gαq, Gβγ), PLCβ and PKC (Gαq, Gα12/13, Gβγ), ions channels (Gβγ), and transactivate tyrosine kinase receptors (HER1 and Gβ for example). GPCR signals mediated by hGP are interrupted or reinitiated by several mechanisms including: i) GPCR phosphorylation by GPCR kinases; ii) Receptor internalization, degradation or recycling; iii) The regulators of G-protein signaling (RGS) working as Gα-GTPase activators; iv) Reassociation of latent Gα-GDP/Gβγ heterotrimers.
Interview with Christian Gespach

Fig. 2 (Left). Aluminium Fluoride AlF4- as a GPCR-independent activator of G-proteins by mimicking the Gα-GTP transition-activated state of Ga-proteins (Ga-GPAI4-). Model of Martin Rodbell dedicated to Christian GESPACH («Bon Succès») during the 1st International Symposium on VIP, PACAP and related regulatory peptides in Strasbourg (Bischenberg, 1993).

level of the retinoblastoma proteins pRb1 and pRb2, src, Wnt receptors Frizzled, CXCR4 /MIF axis, thrombin PAR-1 and their signaling commutators (RhoA/RhoD, the NO/cGMP axis), the Gep oncogenes Gna12/13, the Gαi subunits family including the and Gip2 oncogene Gna2, Gαi3, and Gαolf). The INSERM U482 and U673 Teams (Fig. 5) contributed to major advances on oncogenic pathways controlled by receptor and nonreceptor tyrosine and serine/threonine kinases TGFβ, PKCα, c-kit, leptin, VEGF/semaphorin family and neurotensin), Rho-like small GTPases, trefoil factors family TFF and their connections with src and EGFR, netrin and deleted in colon cancer (DCC dependance receptor and adenosine A2b co-receptor), and functional responses to the estrogen receptor α (ERα)-dependent nuclear transcription factor and repressor WISP-2 and its implication in epithelial-mesenchymal transition (EMT). A significant account of research directed by Gespach was focused on immortalization and transformation of human colon and breast and epithelial cells in order to mimic and characterize genetic, molecular and functional mechanisms at the adenoma-adenoma transition: SV40 Large T, Adenovirus 2 E1A, Ras /TGFβ, Src and Polymya middle T oncogenes (Berthon et al., 1992, Chastre et al., 1991, Emami et al., 1989, Empereur et al., 1997). This strategy was also applied to other genetic diseases such as Myasthenia gravis and Cystic Fibrosis (Chastre et al., 1991, Lemnaouar et al., 1993, Marie et al., 1999). Preclinical studies supporting the therapeutic role of signaling inhibitors and oxaliplatin combined with 5-FU and folinic acid/leucovorin or irinotecan were the basis of current chemotherapy in colorectal cancer, the FOLFOX and FOLFIRI regimens (Andre et al., 2004, Raymond et al., 1997). INSERM U482 was the first laboratory to clone the alternative spliced form of Rac1 encoding the constitutively activated form of this GTPase named Rac1b (Jordan et al., 1999). This important discovery was based on the novel hypothesis of Dr. Gespach that molecular alterations might target the Rho-like small GTPases, as described for Ki-ras mutations in a vast majority of epithelial cancers. The hype started in 2005 when the Bissell group published in Nature a crucial role of Rac1b in matrix metalloproteinase-3 induced EMT and invasion in breast cancer cells (Radisky et al., 2005). As recently reviewed by C. Gespach, clinical breast cancers and several malignant epithelial tumors display EMT signatures and markers with prognosis significance for recurrence, metastasis, overall survival and therapeutic resistances (Sabbah et al., 2008). Christian Gespach was invited as speaker and chairman in more than 40 international meetings.
Tumors and their metastatic niches are complex organs consisting of genetically reprogrammed cancer cells and the tumor stroma (from Greek translated as “bed”). This tumor stroma is also reciprocally “transformed” by cancer cells and consists of complex networks of extracellular matrix (ECM) molecules involved at several interfaces with fibroblasts, adipocytes, mesenchymal stem cells, the vascular and immune systems. Tumor-associated fibroblasts that express α-smooth muscle actin are referred to as myofibroblasts. Myofibroblasts are factories producing multiple growth factors, ECM proteins and proteases to support cancer invasion. Where do we stand today with the clinical applications of this concept?

Several signals from the literature highlight the critical importance of the molecular and cellular crosstalks between cancer cells and their immediate and distant environment, respectively the tumor stroma, mesenchymal stem cells in bone marrow and other tissues, and also from metastatic sites, according to the self-seeding and trafficking theory of the Massague and Weinberg groups (reviewed in Gespach, 2010). It is therefore apparent that the cancer cell-stroma connections are involved in several steps of the neoplastic conversion, including cancer initiation, promotion and progression. Thus, the response of a given malignant tumor to chemotherapy and radiation should be considered in view of the respective roles and sensitivity of these compartments to a given treatment. Drug resistances and cancer cell survival mechanisms originate from these questions. A better knowledge of these mechanisms and therapeutic disruption of their fatal consequence appears to be one of the major challenges for the next 10 years.

A recent Pubmed search revealed less than 400 citations for Rab and cancer. Although belonging to the Ras family of small GTPases, RabGTPases are unexpected players in the cancer signaling field? This contrasts starkly with the founding members of the Ras superfamily small GTPases (H-Ras, Ki-Ras and N-Ras) which are prototypic oncogenes with more than 20,000 hits in Pubmed.

I think that it is not surprising that regulated secretory Rab-GTPases are involved in cancer progression because released products from cancer cells and tumor stroma cells are playing major roles on autocrine, juxtacrine and paracrine regulations and transforming functions in cancer cells, adjacent tumor stroma cells, and systemic regulations of distant metastasis by cancer cell homing and growth. We have greatly contributed to this concept to identify critical secreted factors from cancer cells and tumor stromal cells by using conditioned culture medium and co-culture systems (De Wever et al., 2010, Hendrix et al., 2010).

The Laboratory of Experimental Cancer Research in Ghent and your INSERM group in Paris have a long and successful collaborative tradition. The year 2010 has been very successful with multiple high-impact joined publications and several reciprocal visits in Ghent and Paris. The joint research visits are funded by the Egide and Tournesol program fueling collaboration efforts between the Flemish community and France. What do you feel about the future?

I think that the French and Belgium Research Institutes for Life Sciences should organize and intensify more tightly collaborations supported by a common Institute of Life Science and Technology devoted to Cancer Research and Treatment. A synergy based on science-based Academic Institutions and Pharmaceutical Industry, but not on administration -based in-

---

Fig. 4. GPCR agonists in development, neoplasia and breast cancer.

Fig. 5. Part of the staff in INSERM U673 (Molecular and Clinical Oncology) made up of 55-65 members (Hospital Saint-Antoine, 2006). Heads and main contributors of the Teams: Drs. A. Atfi, L. Levy and C. Prunier (TGFβ and cancer progression); Drs. P. Forgez, C. Gespach, S. Attoub, E. Chastre, S. Emami, G. Reeduith, M. Sabbath (Invasive growth, Angiogenesis in Colon and breast cancers); Pr. A. de Gramont, Drs. A. Larsen and Prs. T. André, S. Faivre and E. Raymond (Preclinical studies and Clinical trials in colorectal cancer).
It think that this report opened new avenues for cancer research and treatment (reviewed in (Emami et al., 2001). Most importantly, Gespach clarified the dual roles of TFFs and their therapeutic potential on wound healing, mucosal repair, transient inflammatory situations and tumorigenesis. In the stomach, TFF1 is a gastric tumor suppressor gene lost by epigenetic silencing. Consistently, TFF1/pS2 is a limiting factor against the erosion of the gastric epithelial cell surface and counteracts inflammatory situations and cancer progression. In breast cancer, TFF1 expression is linked to a favorable -positive state of breast cancers that have a favorable prognosis because of their sensitivity to classical, efficient targeted hormone therapy (reviewed in Gespach, 2008).

References


EMPEREUR, S., DJELLOUL, S., DI GIOIA, Y., BRUYNEEL, E., MAREEL, M., VAN HENGEL, J., VAN ROY, F., COMOGlio, P., COURNETIDGE, S., PARASKEVA, C., et al. (1997). Progression of familial adenomatous polyposis (FAP) colonic cells...
after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion. *Br J Cancer* 75: 241-250.


Further Related Reading, published previously in the *Int. J. Dev. Biol.*

**Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth**
Ellen Van Obberghen-Schilling, Richard P. Tucker, Falk Saupe, Isabelle Gasser, Botond Cseh, Gertraud Orend
*Int. J. Dev. Biol.* (2011) 511 - 525 (doi: 10.1387/ijdb.103243eo)

**Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives**
M. Angela Nieto
*Int. J. Dev. Biol.* (2009) 53: 1541-1547

**Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy**
Ramsey A. Foty and Malcolm S. Steinberg
*Int. J. Dev. Biol.* (2004) 48: 397-409

**The stroma reaction myofibroblast: a key player in the control of tumor cell behavior**
Alexis Desmoulière, Christelle Guyot and Giulio Gabbiani

**Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: an in situ hybridization study**
I Kalemcev, T Yoshida, K Iriyama and T Sakakura
*Int. J. Dev. Biol.* (1997) 41: 569-573

5 yr ISI Impact Factor (2010) = 2.961